A Phase 2 interventional study of VLY-686 (Tradipitant) and Placebo in Gastroparesis, sponsored by Vanda Pharmaceuticals. Completed at 38 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-08-06.
Sponsored by Vanda Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 184 studies in Gastroparesis with a site in United States — 33 open to participants now, 41 under way, 2 of them phase 3. Gastroparesis · United States.
Among the 184 studies in Gastroparesis with a site in United States, this one is the 25th largest by enrollment of the 136 interventional ones that give a count, is one of 4 that started in 2016, is one of 38 in phase 2, and was the 76th registered.
323 studies on the registry are indexed under Gastroparesis; 75 are open to participants now.
Browse Gastroparesis studies →33 of the 184 studies in Gastroparesis with a site in United States are open now. Recruiting first, the newest first:
Evan (Huiliang) Wang · Sites in United States
Ages 18–70
Indiana University · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18–65
Viral N. Shah · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 49 Gastroparesis studies recruiting now, 25 (51%) set no upper age limit and 14 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
184 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 42 · Phase 3 14 · Phase 4 6
First in 2002; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 152 is above the median of 42 across 215 interventional studies indexed under Gastroparesis.
Median enrollment 36 across the 136 interventional studies, 108 across the 39 observational. Of the 124 that completed or were terminated, 63 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
55 of 184 have an industry lead sponsor. The 10 most frequent:
Vanda Pharmaceuticals is the lead sponsor of 82 studies on the registry; 17 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 22 (67%) have results posted.
Vanda Pharmaceuticals has 4 studies filed under Gastroparesis — fewer than ten, so there is no comparison to draw.
14 of the studies in Gastroparesis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01696734Phase 3M.D. Anderson Cancer CenterDomperidone in Treating Patients With Gastrointestinal Disorders | 2027-10-31 |
| NCT04506593Indiana UniversityIndiana University Gastrointestinal Motility Diagnosis Registry | 2026-11 |
| NCT06046833Samita GargContinuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes | 2026-12 |
| NCT02165059Indiana UniversityGI Neuromuscular Pathology Prospective Registry | 2026-12 |
| NCT04282317Indiana UniversityMagnetic Resonance Imaging of the Brain and Stomach in Healthy Volunteers and Gastroparesis | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 184 studies in Gastroparesis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States. One hundred fifty (150) subjects diagnosed with gastroparesis, who satisfy the selection criteria for the study, will be randomized to one of two treatment groups, active or placebo.
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States. One hundred fifty (150) subjects diagnosed with gastroparesis, who satisfy the selection criteria for the study, will be randomized to one of two treatment groups, active or placebo.
The study is divided into two phases: the screening phase and the evaluation phase. The screening phase includes a screening visit to evaluate subjects' preliminary eligibility for the study. During the screening phase, subjects will collect diary data for at least 4 weeks. The evaluation phase includes 4 weeks of randomized double-blind treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
VLY-686 (Tradipitant) oral capsule for 4 weeks.
Drug: VLY-686 (Tradipitant)
Placebo oral capsule for 4 weeks.
Other: Placebo
oral capsule
placebo oral
Change From Baseline in Average Nausea Severity
The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients to rate the worst occurrence of each cardinal symptom of gastroparesis (nausea severity, early satiety, postprandial fullness, bloating, and abdominal pain) in the past 24 hours on a Likert scale from 0 (no symptoms) to 5 (very severe). Change from baseline in average nausea severity score is calculated as the weekly average post value minus baseline value of the daily nausea severity score from the GCSDD. A negative change indicates improvement.
Time frame: 4 weeks
Weekly % Nausea-Free Days
The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients if they have had any nausea over the past 24 hours and if yes, to rate the worst occurrence in the past 24 hours on a Likert scale from 1 (very mild) to 5 (very severe). Change in weekly percentage of nausea-free days from baseline is calculated as weekly average post value minus baseline value. Baseline is defined as the average of all nonmissing values in the screening phase (4 weeks).
Time frame: 4 weeks
Daily Average Vomiting Frequency, Change From Baseline
The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients if they have vomited in the past 24 hours and how many times they vomited in the past 24 hours. Change from baseline in the weekly average of daily vomiting frequency is calculated as the weekly average post value minus baseline value of the daily daily vomiting frequency from the GCSDD. Baseline is defined as the average of all non-missing values in the screening phase (4 weeks). A negative change indicates improvement.
Time frame: 4 weeks
Gastroparesis Cardinal Symptom Index (GCSI), Change From Baseline
The GCSI is a subject reported outcome administered in-clinic with a 2-week recall period to measure the severity of symptoms in gastroparesis. The GCSI is composed of 9 items based on three subscales: post-prandial fullness/early satiety (4 items); nausea/vomiting (3 items), and bloating (2 items). The severity of each symptom is rated on a six-point Likert response scale. The minimal scale value = 0 (none) and the maximum scale value = 5 (very severe). GCSI Total score is constructed as the average of the three symptom sub-scales. Higher score is indicative of greater symptom severity.
Time frame: 4 weeks
PAGI-SYM, Change From Baseline
The PAGI-SYM is a patient reported outcome which asks patients to describe the severity of their symptoms over the last two weeks to measure symptom severity for gastroparesis, functional dyspepsia, and gastroesophageal reflux disease. The measure consists of 20 symptom severity items, which cover the following domains: nausea/vomiting, fullness/early satiety, bloating, upper abdominal pain, heartburn/regurgitation, and lower abdominal pain. This questionnaire includes the Gastroparesis Cardinal Symptom Index (GCSI). The severity of each symptom is rated on a six-point Likert response scale. The minimal scale value = 0 (none) and the maximum scale value= 5 (very severe). PAGI-SYM Total score is constructed as the average of the six symptom sub-scales and a higher score is indicative of greater symptom severity.
Time frame: 4 weeks
CGI-S, Change From Baseline
The Clinician Global Impression of Severity (CGI-S) is a 7-point scale on which the clinician rates the severity of the patient's gastroparesis at the time of the assessment and refers to the degree of illness at the time of the visit and during the 2 weeks before the visit. The CGI-S is rated on the following 7-point scale: 1: normal, not at all ill; 2: borderline ill: 3: mildly ill; 4: moderately ill; 5: markedly ill; 6: severely ill; 7: among the most extremely ill patients. Change from baseline is calculated as post value minus baseline value. A negative change indicates improvement.
Time frame: 4 weeks
PGI-C
The Patient Global Impression of Change (PGI-C) is a patient reported questionnaire with a 7-point rating scale where the participant rates his/her own improvement in overall symptoms relative to the baseline assessment. Is is rated as 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. Higher scores indicate a worse outcome.
Time frame: 4 weeks
| Milestone | Tradipitant | Placebo |
|---|---|---|
| Started | 77 | 75 |
| Completed | 72 | 68 |
| Not completed | 5 | 7 |
| Withdrew: Withdrawal by subject | 3 | 3 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Non-compliance | 0 | 1 |
The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients to rate the worst occurrence of each cardinal symptom of gastroparesis (nausea severity, early satiety, postprandial fullness, bloating, and abdominal pain) in the past 24 hours on a Likert scale from 0 (no symptoms) to 5 (very severe). Change from baseline in average nausea severity score is calculated as the weekly average post value minus baseline value of the daily nausea severity score from the GCSDD. A negative change indicates improvement.
| score on a scale (change from baseline) | Tradipitant | Placebo |
|---|---|---|
| Change From Baseline in Average Nausea Severity | -1.25 (-1.53 to -0.98) | -0.73 (-1.02 to -0.44) |
The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients if they have had any nausea over the past 24 hours and if yes, to rate the worst occurrence in the past 24 hours on a Likert scale from 1 (very mild) to 5 (very severe). Change in weekly percentage of nausea-free days from baseline is calculated as weekly average post value minus baseline value. Baseline is defined as the average of all nonmissing values in the screening phase (4 weeks).
| Percentage (%) of nausea-free days | Tradipitant | Placebo |
|---|---|---|
| Weekly % Nausea-Free Days | 28.81 (21.09 to 36.53) | 15.00 (6.94 to 23.07) |
The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients if they have vomited in the past 24 hours and how many times they vomited in the past 24 hours. Change from baseline in the weekly average of daily vomiting frequency is calculated as the weekly average post value minus baseline value of the daily daily vomiting frequency from the GCSDD. Baseline is defined as the average of all non-missing values in the screening phase (4 weeks). A negative change indicates improvement.
| weekly average of daily vomit episodes | Tradipitant | Placebo |
|---|---|---|
| Daily Average Vomiting Frequency, Change From Baseline | -0.49 (-0.64 to -0.34) | -0.26 (-0.42 to -0.10) |
The GCSI is a subject reported outcome administered in-clinic with a 2-week recall period to measure the severity of symptoms in gastroparesis. The GCSI is composed of 9 items based on three subscales: post-prandial fullness/early satiety (4 items); nausea/vomiting (3 items), and bloating (2 items). The severity of each symptom is rated on a six-point Likert response scale. The minimal scale value = 0 (none) and the maximum scale value = 5 (very severe). GCSI Total score is constructed as the average of the three symptom sub-scales. Higher score is indicative of greater symptom severity.
| score on a scale (change from baseline) | Tradipitant | Placebo |
|---|---|---|
| Gastroparesis Cardinal Symptom Index (GCSI), Change From Baseline | -0.93 (-1.14 to -0.73) | -0.58 (-0.80 to -0.36) |
The PAGI-SYM is a patient reported outcome which asks patients to describe the severity of their symptoms over the last two weeks to measure symptom severity for gastroparesis, functional dyspepsia, and gastroesophageal reflux disease. The measure consists of 20 symptom severity items, which cover the following domains: nausea/vomiting, fullness/early satiety, bloating, upper abdominal pain, heartburn/regurgitation, and lower abdominal pain. This questionnaire includes the Gastroparesis Cardinal Symptom Index (GCSI). The severity of each symptom is rated on a six-point Likert response scale. The minimal scale value = 0 (none) and the maximum scale value= 5 (very severe). PAGI-SYM Total score is constructed as the average of the six symptom sub-scales and a higher score is indicative of greater symptom severity.
| score on a scale (change from baseline) | Tradipitant | Placebo |
|---|---|---|
| PAGI-SYM, Change From Baseline | -0.93 (-1.12 to -0.74) | -0.65 (-0.86 to -0.45) |
The Clinician Global Impression of Severity (CGI-S) is a 7-point scale on which the clinician rates the severity of the patient's gastroparesis at the time of the assessment and refers to the degree of illness at the time of the visit and during the 2 weeks before the visit. The CGI-S is rated on the following 7-point scale: 1: normal, not at all ill; 2: borderline ill: 3: mildly ill; 4: moderately ill; 5: markedly ill; 6: severely ill; 7: among the most extremely ill patients. Change from baseline is calculated as post value minus baseline value. A negative change indicates improvement.
| score on a scale (change from baseline) | Tradipitant | Placebo |
|---|---|---|
| CGI-S, Change From Baseline | -1.13 (-1.36 to -0.91) | -0.74 (-0.98 to -0.50) |
The Patient Global Impression of Change (PGI-C) is a patient reported questionnaire with a 7-point rating scale where the participant rates his/her own improvement in overall symptoms relative to the baseline assessment. Is is rated as 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. Higher scores indicate a worse outcome.
| score on a scale (change from baseline) | Tradipitant | Placebo |
|---|---|---|
| PGI-C | 2.66 (2.40 to 2.93) | 3.06 (2.78 to 3.35) |
The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients to rate the worst occurrence of each cardinal symptom of gastroparesis (nausea severity, early satiety, postprandial fullness, bloating, and abdominal pain) in the past 24 hours on a Likert scale from 0 (no symptoms) to 5 (very severe). Change from baseline in average nausea severity score is calculated as the weekly average post value minus baseline value of the daily nausea severity score from the GCSDD. A negative change indicates improvement.
| score on a scale (change from baseline) | Tradipitant | Placebo |
|---|---|---|
| Change From Baseline in Average Nausea Severity; Baseline Vomiting Group | -1.43 (-1.72 to -1.14) | -0.42 (-0.76 to -0.07) |
The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients to rate the worst occurrence of each cardinal symptom of gastroparesis in the past 24 hours on a scale from 0 (no symptoms) to 5 (very severe).
| Percentage (%) of nausea-free days | Tradipitant | Placebo |
|---|---|---|
| GCSDD, % Nausea-Free Days; Baseline Vomiting Group | 32.3 (23.8 to 40.8) | 7.6 (-2.3 to 17.5) |
The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients to rate the worst occurrence of each cardinal symptom of gastroparesis in the past 24 hours on a scale from 0 (no symptoms) to 5 (very severe). Change from baseline is calculated as post value minus baseline value. A negative change indicates improvement.
| weekly average of daily vomit episodes | Tradipitant | Placebo |
|---|---|---|
| GCSDD, Daily Average Vomiting Frequency, Change From Baseline; Baseline Vomiting Group | -0.69 (-0.89 to -0.49) | -0.32 (-0.56 to -0.08) |
The GCSI is a subject reported outcome administered in-clinic with a 2-week recall period to measure the severity of symptoms in gastroparesis. The GCSI is composed of 9 items based on three subscales: post-prandial fullness/early satiety (4 items); nausea/vomiting (3 items), and bloating (2 items). The severity of each symptom is rated on a six-point Likert response scale. The minimal scale value = 0 (none) and the maximum scale value = 5 (very severe). GCSI Total score is constructed as the average of the three symptom sub-scales. Higher score is indicative of greater symptom severity.
| score on a scale (change from baseline) | Tradipitant | Placebo |
|---|---|---|
| Gastroparesis Cardinal Symptom Index (GCSI), Change From Baseline; Baseline Vomiting Group | -1.10 (-1.33 to -0.87) | -0.60 (-0.88 to -0.32) |
The PAGI-SYM is a patient reported outcome which asks patients to describe the severity of their symptoms over the last two weeks to measure symptom severity for gastroparesis, functional dyspepsia, and gastroesophageal reflux disease. The measure consists of 20 symptom severity items, which cover the following domains: nausea/vomiting, fullness/early satiety, bloating, upper abdominal pain, heartburn/regurgitation, and lower abdominal pain. This questionnaire includes the Gastroparesis Cardinal Symptom Index (GCSI). The severity of each symptom is rated on a six-point Likert response scale. The minimal scale value = 0 (none) and the maximum scale value= 5 (very severe). PAGI-SYM Total score is constructed as the average of the six symptom sub-scales and a higher score is indicative of greater symptom severity.
| score on a scale (change from baseline) | Tradipitant | Placebo |
|---|---|---|
| PAGI-SYM, Change From Baseline; Baseline Vomiting Group | -1.06 (-1.28 to -0.85) | -0.69 (-0.95 to -0.43) |
The Clinician Global Impression of Severity (CGI-S) is a 7-point scale on which the clinician rates the severity of the patient's gastroparesis at the time of the assessment and refers to the degree of illness at the time of the visit and during the 2 weeks before the visit. The CGI-S is rates on the following 7-point scale: 1: normal, not at all ill; 2: borderline ill: 3: mildly ill; 4: moderately ill; 5: markedly ill; 6: severely ill; 7: among the most extremely ill patients. Change from baseline is calculated as post value minus baseline value. A negative change indicates improvement.
| score on a scale (change from baseline) | Tradipitant | Placebo |
|---|---|---|
| CGI-S, Change From Baseline; Baseline Vomiting Group | -1.24 (-1.49 to -0.99) | -0.79 (-1.08 to -0.49) |
The Patient Global Impression of Change (PGI-C) is a patient reported questionnaire with a 7-point rating scale where the participant rates his/her own improvement in overall symptoms relative to the baseline assessment. Is is rated as 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. Higher scores indicate a worse outcome.
| score on a scale (change from baseline) | Tradipitant | Placebo |
|---|---|---|
| PGI-C; Baseline Vomiting Group | 2.52 (2.24 to 2.81) | 3.24 (2.90 to 3.59) |
Defined as a nausea score of very mild or better (≤1) in average daily nausea severity at week 4. Nausea severity is rated on a Likert scale from 0 (none) to 5 (very severe).
| Percentage (%) of nausea responders | Tradipitant | Placebo |
|---|---|---|
| Nausea Responder Rate (%) | 32.9 | 11.8 |
Defined as a nausea score of very mild or better (≤1) in average daily nausea severity at week 4. Nausea severity is rated on a Likert scale from 0 (none) to 5 (very severe).
| Percentage (%) of nausea responders | Tradipitant | Placebo |
|---|---|---|
| Nausea Responder Rate (%); Baseline Vomiting Group | 36.2 | 6.9 |
Defined as a nausea score of 0 in at week 4. Nausea severity is rated on a Likert scale from 0 (none) to 5 (very severe).
| Percentage (%) of participants | Tradipitant | Placebo |
|---|---|---|
| Complete Nausea Responder Rate (%) | 15.07 | 4.4 |
Defined as a nausea score of 0 at week 4. Nausea severity is rated on a Likert scale from 0 (none) to 5 (very severe).
| Percentage (%) of participants | Tradipitant | Placebo |
|---|---|---|
| Complete Nausea Responder Rate (%); Baseline Vomiting Group | 17.24 | 4.65 |
Defined as 1-point or greater improvement on their GCSI total score from baseline to week 4. The GCSI is a subject reported outcome. Part I consists of the traditional GCSI and severity rating of upper abdominal pain and severity of overall symptoms on a 0 (none) to 5 (very severe) Likert scale. Part II uses a 7-point rating scale for the subject to rate their own improvement relative to baseline. Symptoms are rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. The GCSI subscale scores, nausea/vomiting (3 items), postprandial fullness/early satiety (4 items), bloating (2 items), and upper abdominal pain (2 items), are calculated by taking the mean of non-missing items in each subscale; the subscale scores vary from 0 (none or absent) to 5 (very severe). The total score is calculated by taking the mean of the three subscales (except upper abdominal pain and overall symptom item).
| Percentage (%) | Tradipitant | Placebo |
|---|---|---|
| Percentage of Participants With Clinically Meaningful Improvement on Total GCSI Score | 46.6 | 23.5 |
Defined as 1-point or greater improvement on their GCSI total score from baseline to week 4. The GCSI is a subject reported outcome. Part I consists of the traditional GCSI and severity rating of upper abdominal pain and severity of overall symptoms on a 0 (none) to 5 (very severe) Likert scale. Part II uses a 7-point rating scale for the subject to rate their own improvement relative to baseline. Symptoms are rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. The GCSI subscale scores, nausea/vomiting (3 items), postprandial fullness/early satiety (4 items), bloating (2 items), and upper abdominal pain (2 items), are calculated by taking the mean of non-missing items in each subscale; the subscale scores vary from 0 (none or absent) to 5 (very severe). The total score is calculated by taking the mean of the three subscales (except upper abdominal pain and overall symptom item).
| Percentage (%) | Tradipitant | Placebo |
|---|---|---|
| Percentage of Participants With Clinically Meaningful Improvement on Total GCSI Score; Baseline Vomiting Group | 51.7 | 23.3 |
Collected over 8 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tradipitant | 0/77 (0%) | 0/77 (0%) | 31/77 (40.3%) |
| Placebo | 0/75 (0%) | 1/75 (1.3%) | 20/75 (26.7%) |
| Event | Tradipitant | Placebo |
|---|---|---|
| SyncopeNervous system disorders | 0/77 | 1/75 |
| Event | Tradipitant | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 2/77 | 5/75 |
| DiarrheaGastrointestinal disorders | 4/77 | 3/75 |
| HeadacheNervous system disorders | 1/77 | 3/75 |
| SomnolenceNervous system disorders | 3/77 | 0/75 |
| FatigueGeneral disorders | 3/77 | 1/75 |
| Abdominal painGastrointestinal disorders | 2/77 | 2/75 |
| DizzinessNervous system disorders | 2/77 | 2/75 |
| Abdominal pain upperGastrointestinal disorders | 2/77 | 0/75 |
| Dry mouthGastrointestinal disorders | 2/77 | 0/75 |
| RashSkin and subcutaneous tissue disorders | 2/77 | 0/75 |
| Age, Continuous(years) | Tradipitant | Placebo | Total |
|---|---|---|---|
| Mean | 45.4 ± 13.16 | 46.4 ± 13.46 | 45.9 ± 13.28 |
| Sex: Female, Male(Participants) | Tradipitant | Placebo | Total |
|---|---|---|---|
| Female | 69 | 68 | 137 |
| Male | 8 | 7 | 15 |
| Race (NIH/OMB)(Participants) | Tradipitant | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 2 | 3 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 9 | 7 | 16 |
| White | 66 | 65 | 131 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Disease Etiology(Participants) | Tradipitant | Placebo | Total |
|---|---|---|---|
| Idiopathic | 46 | 45 | 91 |
| Diabetic | 31 | 30 | 61 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2016 to primary completion in Nov 2018, 24 months.
Results were first posted in Aug 2024, 5 years 9 months after primary completion.
Of 20 phase 2 interventional studies under Gastroparesis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 24 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tradipitant